Cibele Dal Fabbro, Philippe Harris, Eric Dufresne, Alberto Herrero Babiloni, Pierre Mayer, Houda Bahig, Edith Filion, Felix Nguyen, Julien Ghannoum, Matthieu Schmittbuhl, Gilles Lavigne
{"title":"Orofacial Pain and Snoring/Obstructive Sleep Apnea in Individuals with Head and Neck Cancer: A Critical Review.","authors":"Cibele Dal Fabbro, Philippe Harris, Eric Dufresne, Alberto Herrero Babiloni, Pierre Mayer, Houda Bahig, Edith Filion, Felix Nguyen, Julien Ghannoum, Matthieu Schmittbuhl, Gilles Lavigne","doi":"10.11607/ofph.3176","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>(1) To summarize current knowledge on the prevalence, intensity, and descriptors of orofacial pain and snoring/obstructive sleep apnea (OSA) before and after head and neck cancer (HNC) treatment; and (2) to propose future directions for research.</p><p><strong>Methods: </strong>The median prevalence for each condition was estimated from the most recent systematic reviews (SRs) and updated with new findings retrieved from the PubMed, Web of Science, Embase, and Cochrane databases up to December 2021.</p><p><strong>Results: </strong>The prevalence of HNC pain seems relatively stable over time, with a median of 31% before treatment in three studies to a median of 39% at 1 month to 16 years after treatment in six studies. HNC pain intensity remains mild to moderate. There was a threefold increase in temporomandibular pain prevalence after surgery (median 7.25% before to 21.3% after). The data for snoring prevalence are unreliable. The OSA/HNC prevalence seems relatively stable over time, with a median of 72% before treatment in three studies to 77% after treatment in 14 studies.</p><p><strong>Conclusion: </strong>With the exception of temporomandibular pain, the prevalence of HNC pain and OSA seems to be stable over time. Future studies should: (1) compare the trajectory of change over time according to each treatment; (2) compare individuals with HNC to healthy subjects; (3) use a standardized and comparable method of data collection; and (4) assess tolerance to oral or breathing devices, since HNC individuals may have mucosal sensitivity or pain.</p>","PeriodicalId":1,"journal":{"name":"Accounts of Chemical Research","volume":null,"pages":null},"PeriodicalIF":16.4000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10586573/pdf/","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Accounts of Chemical Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.11607/ofph.3176","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 1
Abstract
Aims: (1) To summarize current knowledge on the prevalence, intensity, and descriptors of orofacial pain and snoring/obstructive sleep apnea (OSA) before and after head and neck cancer (HNC) treatment; and (2) to propose future directions for research.
Methods: The median prevalence for each condition was estimated from the most recent systematic reviews (SRs) and updated with new findings retrieved from the PubMed, Web of Science, Embase, and Cochrane databases up to December 2021.
Results: The prevalence of HNC pain seems relatively stable over time, with a median of 31% before treatment in three studies to a median of 39% at 1 month to 16 years after treatment in six studies. HNC pain intensity remains mild to moderate. There was a threefold increase in temporomandibular pain prevalence after surgery (median 7.25% before to 21.3% after). The data for snoring prevalence are unreliable. The OSA/HNC prevalence seems relatively stable over time, with a median of 72% before treatment in three studies to 77% after treatment in 14 studies.
Conclusion: With the exception of temporomandibular pain, the prevalence of HNC pain and OSA seems to be stable over time. Future studies should: (1) compare the trajectory of change over time according to each treatment; (2) compare individuals with HNC to healthy subjects; (3) use a standardized and comparable method of data collection; and (4) assess tolerance to oral or breathing devices, since HNC individuals may have mucosal sensitivity or pain.
目的:(1)总结头颈癌(HNC)治疗前后口面部疼痛和打鼾/阻塞性睡眠呼吸暂停(OSA)的患病率、强度和描述因素;(2)提出未来的研究方向。方法:根据最新的系统评价(SRs)估计每种疾病的中位患病率，并根据截至2021年12月PubMed、Web of Science、Embase和Cochrane数据库检索的新发现进行更新。结果:随着时间的推移，HNC疼痛的患病率似乎相对稳定，治疗前的中位数为31%，6项研究治疗后1个月至16年的中位数为39%。HNC疼痛强度仍为轻度至中度。术后颞下颌关节疼痛患病率增加了三倍(术前中位数为7.25%，术后中位数为21.3%)。关于打鼾患病率的数据是不可靠的。随着时间的推移，OSA/HNC患病率似乎相对稳定，3项研究治疗前的中位数为72%，14项研究治疗后的中位数为77%。结论:除了颞下颌疼痛外，HNC疼痛和OSA的患病率似乎是稳定的。未来的研究应:(1)比较每一种治疗方法随时间的变化轨迹;(2)将HNC个体与健康人进行比较;(3)采用标准化和可比较的数据收集方法;(4)评估对口腔或呼吸装置的耐受性，因为HNC患者可能有粘膜敏感或疼痛。
期刊介绍：
Accounts of Chemical Research presents short, concise and critical articles offering easy-to-read overviews of basic research and applications in all areas of chemistry and biochemistry. These short reviews focus on research from the author’s own laboratory and are designed to teach the reader about a research project. In addition, Accounts of Chemical Research publishes commentaries that give an informed opinion on a current research problem. Special Issues online are devoted to a single topic of unusual activity and significance.
Accounts of Chemical Research replaces the traditional article abstract with an article "Conspectus." These entries synopsize the research affording the reader a closer look at the content and significance of an article. Through this provision of a more detailed description of the article contents, the Conspectus enhances the article's discoverability by search engines and the exposure for the research.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
